AbCellera and Biogen link on neurological antibody therapy

2024-03-12
Pharmaceutical Technology
孤儿药引进/卖出
AbCellera and Biogen link on neurological antibody therapy
Preview
来源: Pharmaceutical Technology
AbCellera and Biogen will execute the discovery and development of antibodies for neurological conditions. Credit: Gorodenkoff / Shutterstock.com.
AbCellera has entered a partnership with Biogen to discover therapeutic antibodies for neurological ailments.
The companies will execute the discovery and development of antibodies for a new target that will aid in offering brain biotherapeutics for neurological indications.
AbCellera will receive an upfront payment from Biogen.
Biogen will also make milestone payments when research programmes meet specific research, developmental and regulatory goals, apart from royalty payments on future net product sales.
AbCellera leverages a new approach to discover antibody drugs to expedite the development of treatment options.
See Also:
Pearl Bio and Merck partner for discovery of cancer therapies
AbCellera and Biogen link on neurological antibody therapy
Preview
来源: Pharmaceutical Technology
Terns scores FDA orphan designation for CML therapy
AbCellera and Biogen link on neurological antibody therapy
Preview
来源: Pharmaceutical Technology
The company’s integrated engine combines expertise, technology and data science to advance antibody-based treatments across a range of therapeutic areas.
The collaboration with Biogen leverages AbCellera’s expertise in complex challenges in neurological disease.
In November 2023, AbCellera signed a multi-year, multi-programme deal with Prelude Therapeutics.
The collaboration focuses on the discovery, development and marketing of treatments for cancer patients.
Prelude contributes its expertise in targeted protein degradation and AbCellera provides its antibody discovery engine to develop novel precision antibody-drug conjugates.
AbCellera Partnering senior vice-president Murray McCutcheon stated: “Delivering biologics across the blood-brain barrier is one of the most important and long-standing problems in neuroscience.
“We are excited to work with Biogen on this innovative programme, which has the potential to unlock multiple new approaches to treating neurological conditions.”
In September 2023, AbCellera also initiated a strategic collaboration with Incyte, targeting the discovery and development of therapeutic antibodies in oncology.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。